Warren M. Kati

The University of Texas MD Anderson Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

40h-index6.0kcitations203works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(108), Multiple Myeloma Research and Treatments(90), HIV/AIDS drug development and treatment(52), Hepatitis C virus research(37), CAR-T cell therapy research(25)

Publications203 total

Data from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Data from <i>HEXIM1</i> as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
2023Open Access
Data from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Supplemental Figure 1 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Figure S5 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Supplemental Figures 1-4; Supplemental Tables 2,4,5 from <i>HEXIM1</i> as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
2023Open Access
Table S1 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Figure S2 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Figure S4 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Supplemental Figure 6 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Supplemental Table 3 from <i>HEXIM1</i> as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
2023Open Access
Figure S4 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Figure S5 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Supplemental Figure 4 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Supplemental Figure 2 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Supplemental Figure 6 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Figure S1 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Supplemental Figure 2 from Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
2023Open Access
Figure S3 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
2023Open Access
Supplemental Table 1 from <i>HEXIM1</i> as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Akhteruzzaman Molla(15), Dale J. Kempf(14), Keith F. McDaniel(12), Clarence J. Maring(11), John K. Pratt(10), Yu Shen(10), Daniel H. Albert(9), William E. Kohlbrenner(9), Dachun Liu(8), Preethi Krishnan(8), Kent D. Stewart(7), Emily J. Faivre(7), Xiaoli Huang(7), Yaya Liu(7), Teresa I. Ng(7), Edward Tam(7), Debra Montgomery(7), Hing L. Sham(6), Denise Wilcox(6), Tamar Uziel(6)